Relative Weight of the Variables Evaluated Through the Therapeutic Positioning Reports in the Pricing and Reimbursement of Oncological and Oncohematology Medicines in Spain

The white paper available only in Spanish language

By Bordoy Coma-Cros Clara, Cruz Arrioja Jessica, Manau Vilalta Marc, Castillo Gutiérrez Chus, Vázquez Roso Manuel

Pricing & reimbursement (P&R) decisions for new drugs in Spain are based on the criteria set in the Law on Guarantees and Rational Use of Medicinal Products (LGURM) (RD 1/2015), and the clinical evidence, economic value, and positioning of each new drug in relation to the Therapeutic Positioning Report (TPR). Despite this clear framework, the weight of each criterion on P&R decisions is not transparent.

For oncology therapies in particular, timeline of the P&R decision is critical, however, the gap between the approval of new medicines by EMA and their reimbursement in Spain can be noticeable. As of January 2022, more than 100 TPRs had a delay of 400 days. Both clinicians and patients regret these delays in access and want to streamline evaluation processes with new TPRs.

This white paper explores how companies’ target prices are impacted by the different variables leveraged during the P&R process for oncology and oncohematology’s first indication.

White Paper Summary: Methodology, results, and recommendations

Based on LGURM and TPRs, hypotheses around the relationship between different variables and expected price were developed. Then, using the Wilcoxon or Kruskal-Wallis tests, those hypotheses were statistically analyzed.

Although the process is complex and heterogeneous, the additional clinical benefit is a statistically significant criterion in the decision-making process. While there is no statistically significant relationship between other factors when predicting P&R results, there are interesting trends.

A more structured, transparent, and predictable methodology that considers LGURM priorities would help set expectations and communication among stakeholders. Despite the limited sample, the results can serve as a starting point to increase transparency and improve process structure to encourage a more fluid dialogue in evaluating and financing drugs in Spain.

Have questions or comments about the white paper “Relative Weight of the Variables Evaluated Through the Therapeutic Positioning Reports in the Pricing and Reimbursement of Oncological and Oncohematology Medicines in Spain”? Contact us.

Publications
Published on:
October 5, 2022
Written by:
Bordoy Coma-Cros Clara, Cruz Arrioja Jessica, Manau Vilalta Marc, Castillo Gutiérrez Chus, Vázquez Roso Manuel

Related news

Blog March 20, 2023
The State of Market Access in Italy 2023
To learn about the state of market access in Italy today, we spoke with Giovanni Firenze, Director of Market Access Italy for Alira Health, who attended the recent 2023 Conferenza Nazionale(...)
Drug Development Market Access Pharma
Events March 6, 2023
World EPA Congress 2023
We are pleased to share that we will be participating in World EPA Congress 2023 as speakers and sponsors. World Evidence, Pricing and Access Congress is Europe’s largest congress(...)
Biotech Market Access Pharma Real-World Evidence
Blog March 6, 2023
Market Access in Catalonia: 2022 Trends and What’s Next
Alira Health contributed to the recently published 2022 BioRegion Report, the most extensive analysis of the assets, achievements, and trends in the life sciences and healthcare sector(...)
Biotech Market Access MedTech
Events February 21, 2023
sTARTUp Day 2023
We are pleased to announce that we will be joining sTARTUp Day 2023 as speakers. This unique event will bring together startup-minded people to celebrate entrepreneurship in the city of Tartu.
Healthcare Technology Market Access Spain Startups
News February 21, 2023
Access and reimbursement pathways for digital health solutions and IVD devices
Digital therapeutics (DTx) are innovative solutions that use meaningful data to provide evidence-based decisions for the prevention, treatment, and management of diseases. Particular(...)
Diagnotics Digital Therapeutics Market Access Regulatory
News February 13, 2023
Alira Health Contributes to 2022 Bioregion Report on the Future of Catalan Life Sciences
We are pleased to announce that Alira Health is a key contributor to the just released 2022 Bioregion Report, the benchmark study that analyzes the life sciences and healthcare sector in Catalonia.
Market Access
Events February 9, 2023
2022 BioRegion Report Presentation
We are excited to announce that we will be joining as speakers at the annual presentation of the 2022 BioRegion of Catalonia Report.
BioRegion Market Access
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.